Co-delivery of the NKT agonist -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

Author(s):
Ghinnagow, R.; Meester, J. de; Cruz, L.J.; Aspord, C.; Corgnac, S.; Macho-Fernandez, E.; Soulard, D.; Fontaine, J.; Chaperot, L.; Charles, J.; Soncin, F.; Mami-Chouaib, F.; Plumas, J.; Faveeuw, C.; Trottein, F.
Published
2017
Publication type
Article / Letter to editor
Cancerdendritic cellsnatural killer T cellsself antigenstargetingvaccine
Date issued
2017-12-31
Language
English
Is part of
OncoImmunology (2017), No. 9
hdl
1887/115392
doi
10.1080/2162402X.2017.1339855